COMPARISON OF DIFFERENT TREATMENT MODALITIES OF CHELATION THERAPY IN BETA THALASSEMIA MAJOR PATIENTS
Keywords:
Thalassemia, iron chelating, agents, Deferoxamine, Drug therapy, CombinationAbstract
Background: Thalassemia has high prevalence and carrier rate of 8 – 10% in Pakistan, repeated blood transfusions lead to iron deposition in organs. In this Prospective study we have compared the efficacy of three chelation regimens being used in our country. It has been conducted at PBTS, Fatmid Foundation and Children Hospital Lahore. Methods: 60 thalassemia major patients, were divided into 3 groups according to their mode of chelation. Patients in group I were on oral iron chelator deferiprone, 7 days per week. Thalassemics in group II were on parenteral iron chelator deferoxamine given subcutaneously for 4 days in a week, and group III patients were on combination therapy, deferiprone for 5 days & deferoxamine given twice weekly. The assessment of chelation was done by measurement of serum ferritin and 24 hour urinary iron excretion at the start of study and then after six months of follow up. To assess the hepatic iron, hepatic MRI were also performed. Results: Ferritin levels were maximally decreased in group II, followed by group III, with no significant reduction in group I. However statistically significant difference in mean urinary iron excretion (increased) was seen in group III. The hepatic iron was very high in all three groups as shown by the hepatic MRI. Conclusion: Combination chelation therapy is the most effective chelation therapy in iron overloaded patients. It helps improve the compliance and increases urinary iron excretion. Patients on DFX have lowest degree of hepatic siderosis even though it is considerably higher than normal population.References
Waheed N, Ali S, Butt MA. Comparison of deferiprone and deferrioxamine for treatment of transfusional iron overload in children with beta thalassemia major. J Ayub Med Coll Abbottabad 2014;26(3):297–300.
Settin AA, Al-Haggar MM, Neamatallah M, Al-Said AM, Hafez MM. Detection of beta thalassemia mutations using primer specific amplification compared to revised dot blot hybridization technique in Egyptian cases. Hematol 2006;9(3):401–9.
Angastinosis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998;850:251–69.
Angulo IL, Covas DT, Carneiro AA, Baffa O, Elias Junior J, Vilela G. Determination of iron overload in thalassemia by hepatic MRI and ferritin. Rev Bras Hematol E Hemoter 2008;30:449–52.
Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassemia patients. Expert Opin Pharmacother 2003;4:1763–74.
Alústiza Echeverría JM, Castiella Eguzkiza A, Zapata Morcillo E, Jáuregui Garmendia L, Gabilondo Aguirregabiria A, Paloc C. Quantification of liver iron concentration using 1-Telsa MRI. Radiologica, 2000;50(4):303–7.
De Sanctis, Katz, M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height in beta thalassemia major. Clin Endocrinol (Oxf) 1994;40(6):791–8.
De Sanctis V, Angola G, Wonke B. The development of Diabetes Mellitus in chronic liver disease in ;long term chelated β thalassemia patients. Postgrad Med J 19986;62(731):831–6.
Gandon Y, Guyades D, Heautot JF. Hemachromatosis: diagnosis and quantification of liver iron with gradient echo MRI imaging. Radiology 1994;193(2):533–8.
Kontoghires GJ, Pattichi K, Hadjigariel M, Kolnagou A. Transfusional iron overload and chelation therapy with desferrioxamine and deferiprone. Transfus Sci 2000;23(3):211–23.
Nadeem I, Khalid H, Muhammad Y, Samina A. Ferritin levels in patients of beta thalassaemia major. Intl J Pathol 2004;2(2):71–4.
Weatherall D, Hoffbrand AV. Hemoglobin and its Inherited disorders. In: Hoffbrand AV, Tuddenham E, Catovsky D, editors. 5th edition. Postgraduate Hematology. Blackwell Publishing Oxford. 2005; p.44–58.
Rahman M, Lodhi Y. Prospects and future of conservative management of beta thalassemia major in a developing country. Pak J Med Sci 2004;20:105–12.
Hoffbrand AV, Cohen, AR, Hershko C. Role of Deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102(1):17–24.
Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al. Long term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trail. Br J Hematol 1992;82(2):460–6.
Brogan-pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in Desferrioxamine and Deferiprone treated patients with thalassemia major. Blood 2006;107(9):3733–7.
Wonke B, Wright C, Hoffbrand AV. Combined therapy with desferrioxamine and deferiprone. Br J Hematol 1988;103(2):361–4.
Gomber S, Saxena R, Madan N. Comparative efficacy desferrioxamine, deferiprone and in combination on iron chelation in thalassemia children, Indian Pediatr 2004;41(1):21–7.
Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, et al. Combined therapy with deferiprone & desferrioxamine in thalassemia major. Hematologica 2005;90(10):1309–14.
Oliveri NF, Brittenham GM. Iron chelation therapy and treatment of thalassemia. Blood 1997;89(3):739–61.
Wood J, Enriquez C, Ghure N, Tyzke M, Carson S, Nelson M, et al. MRI R1 and R2 mapping accurately estimates hepatic iron concentration in transfusion dependent thalassemia and sickle cell patients. Blood 2005;106(4):1460–5.
Ejaz MS, Baloch S, Arif F. Efficacy and adverse effects of oral chelating therapy (deferasirox) in multitransfused Pakistani children with beta thalassemia major. Pak J Med Sci 2015;31(3):621–5.
Sajid R, Ghani F, Adil S, Khurshid M. Oral iron chelation therapy with deferiprone in patients with thalassemia major. J Pak Med Assoc 2009;59(6):388–90.
Additional Files
Published
Issue
Section
License
Copyright (c) 2024 Ghazal Usman, Mahfooz ur Rehman, Shifa Khalil, Muhammad Sarmad Hafeez
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
